Market-Moving News for April 25th
$CDTX
$OPTN
$ULBI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CDTX alert in real time by email
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 3/12/2025 | $46.00 | Mkt Outperform | Citizens JMP | |
| 1/27/2025 | Overweight | Cantor Fitzgerald | ||
| 1/3/2025 | $5.00 → $18.00 | Buy | H.C. Wainwright | |
| 12/13/2024 | $34.00 | Outperform | RBC Capital Mkts | |
| 11/8/2024 | $33.00 | Buy | Guggenheim | |
| 8/14/2024 | $24.00 | Neutral → Buy | H.C. Wainwright | |
| 3/11/2024 | $5.00 | Buy | H.C. Wainwright | |
| 8/21/2023 | $3.00 | Buy | Lake Street |
YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter and full year of 2024 and corporate updates, before market open, on Thursday, March 20, 2025. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, March 20, 2025. Participants may access the conference call live via webcast by visiting the Investors section of Opti
NEWARK, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI), today announced that it has filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission in connection with its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The extension is necessary to allow for the completion of the accounting close and financial results audit of Electrochem Solutions, Inc., which the Company acquired on October 31, 2024. The Company expects to file its Form 10-K with the Securities and Exchange Commission as soon as practicable, and no later than April 1, 2025, in accordance with Rule 12b-25. In addition, the Company will r
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program
Citizens JMP initiated coverage of Cidara Therapeutics with a rating of Mkt Outperform and set a new price target of $46.00
Cantor Fitzgerald resumed coverage of Cidara Therapeutics with a rating of Overweight
H.C. Wainwright reiterated coverage of OptiNose with a rating of Buy and set a new price target of $18.00 from $5.00 previously
Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Frank Karbe, MBA, has been appointed Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing to pursue other professional opportunities. Dr. Shah will serve as a consultant to the Company. "We are pleased to welcome Frank to the team as we advance our long-acting influenza antiviral drug CD388 through the e
NEWARK, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) today announced the appointment of Jeffrey Luke as Chief Marketing Officer and James Pope as Senior Vice President - Sales & Business Development, Battery & Energy Products, effective January 6, 2025. As Chief Marketing Officer, Jeff will be responsible for reframing our corporate and brand strategies, providing alignment and accountability throughout the global organization. He will collaborate closely with our sales and engineering teams to develop and execute effective go-to-market strategies, ensuring that Ultralife's products and solutions meet the evolving needs of our customers. Jeff brings over two
4 - OptiNose, Inc. (0001494650) (Issuer)
4 - OptiNose, Inc. (0001494650) (Issuer)
4 - OptiNose, Inc. (0001494650) (Issuer)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
NT 10-K - ULTRALIFE CORP (0000875657) (Filer)
S-8 - Cidara Therapeutics, Inc. (0001610618) (Filer)
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - ULTRALIFE CORP (0000875657) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
YARDLEY, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter and full year of 2024 and corporate updates, before market open, on Thursday, March 20, 2025. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, March 20, 2025. Participants may access the conference call live via webcast by visiting the Investors section of Opti
NEWARK, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI), today announced that it has filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission in connection with its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The extension is necessary to allow for the completion of the accounting close and financial results audit of Electrochem Solutions, Inc., which the Company acquired on October 31, 2024. The Company expects to file its Form 10-K with the Securities and Exchange Commission as soon as practicable, and no later than April 1, 2025, in accordance with Rule 12b-25. In addition, the Company will r
NEWARK, N.Y., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) will report its fourth quarter results for the period ending December 31, 2024 before the market opens on Tuesday, March 11, 2025. Due to the time required to complete the accounting close and audit of the financial results of Electrochem Solutions, Inc., which the Company acquired on October 31, 2024, Ultralife is reporting fourth quarter results later than it has in the past, in contrast to its established practice of reporting fourth quarter results on the Thursday of the sixth week after year end. Ultralife's Management will also host an investor conference call and simultaneous webcast at 8:30 AM ET o